ClinicalTrials.gg
Not yet recruitingNCT07893600Updated Oct 26, 2026

Efficacy and Safety of OsrhCT Before Upper Endoscopy on Improving Visualization of the Gastric Mucosa.

A Phase 2 interventional study of Recombinant Human Chymotrypsin(OsrhCT) 4000U and Placebo for Recombinant Human Chymotrypsin(OsrhCT) in Gastric Mucosal Lesion, sponsored by Healthgen Biotechnology Corp.. Not yet recruiting. Open to participants aged 18 Years to 75 Years. Per ClinicalTrials.gov, last updated 2026-10-26.

Sponsored by Healthgen Biotechnology Corp. · Phase 2, Interventional, and Diagnostic

How we know

Updated Oct 26, 2026Newly registeredGo to Updates ↓

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 2
Study type
Interventional
Enrollment
40
Allocation
Randomized
Ages
18 Years to 75 Years
Sex
All
01

Study summary

Study was designed to evaluate efficacy and safety of OsrhCT before upper endoscopy on visibility of gastric mucosa.

A total of 40 subjects (both male and female) are expected to be enrolled in this trial.

Read the detailed description

This is a single-center, double-blind, randomized study involving 40 patients indicated for diagnostic upper endoscopy. Patients were randomly assigned to one of two arms, with OsrhCT 12000U and matching placebo. The total visibility score was given by the sum of the score 1-4 evaluated for lower esophagus, gastric fundus, upper gastric body, lower gastric body, gastric antrum subsequently by two or three blinded endoscopists. Other parameters monitored were examination time, the amount of water flushed for satisfactory observation of the upper gastrointestinal tract, and incidence of adverse events

02

Conditions studied

  • Gastric Mucosal Lesion

Keywords

  • OsrhCT
  • Recombinant Human Chymotrypsin
03

In context

Lead sponsor

Healthgen Biotechnology Corp. is the lead sponsor of 8 studies on the registry; 4 are open to participants now.

Counted across the registry records on this site, refreshed daily.

04

Who can participate

Ages eligible
18 Years to 75 Years
Sexes eligible
All
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  1. Patients clinically indicated for gastroscopy examination;
  2. Subjects fully understand the content, process, and possible adverse reactions of the trial and voluntary participation with signed ;
  3. Able to complete the research according to the requirements of the experimental plan;
  4. Subjects (including their spouses) voluntarily have no pregnancy plans and use during the study and within 3 months after the last administration of the study drug;
  5. Aged 18-75 years (inclusive), male or female;

Exclusion criteria

Exclusion Criteria:

  1. Known to be allergic to any preparation or anesthesia medication before gastroscopy examination;
  2. Patients plan to undergo gastroscopic treatment, such as endoscopic titanium clip for hemostasis, esophagogastric fundal variceal ligation, endoscopic mucosal stripping, etc;
  3. Subjects disabled to stand sedation anesthesia or gastroscopy examination;
  4. Severe cardiovascular, pulmonary, or cerebral diseases, such as angina, heart failure, and new-onset stroke; or severe liver disease, cirrhosis, or esophagogastric fundus varices;
  5. Suspected or known esophageal fistula, tracheal fistula, intestinal obstruction, active gastrointestinal bleeding, gastric perforation, history of anatomically altered upper GI surgery;
  6. Subjects with a positive result for any of the following at screening: surface antigen (HBsAg), virus antibody (anti-HCV), antibody (anti-HIV), or Treponema pallidum antibody.
  7. Abnormal laboratory values:: (ALT)>2 × , aspartate aminotransferase (AST)>2 × ULN, serum creatinine>1.5 × ULN;
  8. Difficult venous access, inability to tolerate venipuncture for blood collection, or a history of blood- or needle-induced syncope.
  9. Female subjects who had unprotected sex within 14 days prior to screening; Pregnant or breastfeeding women, or who have a positive serum β-HCG test.
  10. Subjects who have participated in any drug clinical trial and received treatment within the last 3 months;
  11. Any other conditions deemed unsuitable for the study by the investigator.
Terms in these criteria, in plain language(7)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Informed consent

Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.

You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.

Contraception

Ways of preventing pregnancy. “Highly effective” methods fail less than 1% of the time a year when used correctly — for example an IUD or an implant.

Criteria usually say which methods count and how long to keep using them after the last dose, sometimes for male participants too. Some studies accept a partner’s vasectomy if it was confirmed successful and that person is the participant’s only sexual partner.

Hepatitis B tests

Hepatitis B is a virus that infects the liver. These are separate tests: HBsAg positive usually means a current infection (a recent vaccination can briefly cause it too); total anti-HBc (HBcAb) positive means an infection now or in the past; HBV DNA measures how much virus is in the blood.

Some studies accept a past infection if HBV DNA is undetectable, sometimes with antiviral medicine during the study. Check what this study allows.

Hepatitis C tests

Hepatitis C is a virus that infects the liver. An HCV antibody test can stay positive after an infection has cleared (and is occasionally positive without one); an HCV RNA test shows whether the virus is there now.

After treatment, hepatitis C counts as cured when HCV RNA is still undetectable 12 weeks or more after the treatment ended. Studies often accept people cured this way.

HIV

The human immunodeficiency virus, which weakens the immune system.

Many studies now accept people whose HIV is controlled on treatment, judged by the viral load and the CD4 count. Check the limits this study sets.

ALT and AST (liver enzymes)

Two enzymes measured in a routine blood test of the liver. Higher levels can mean the liver is under strain or damaged. SGPT and SGOT are older names for ALT and AST.

Criteria usually give a limit as a multiple of the upper limit of normal (ULN), often higher when cancer has spread to the liver.

ULN (upper limit of normal)

The top of the normal range for a blood test, as set by the laboratory that runs it. Each lab prints its own range next to your result.

“≤ 2.5 × ULN” means the result can be up to two and a half times that top value.

05

Study design

Phase
Phase 2
Primary purpose
Diagnostic
Allocation
Randomized
Intervention model
Parallel assignment
Masking
Quadruple (Participant, Care provider, Investigator, Outcomes assessor)
Enrollment
40 participants (estimated)

Study arms

  • Experimental
    Recombinant Human Chymotrypsin(OsrhCT) 12000U

    Recombinant Human Chymotrypsin(OsrhCT) 4000U/bag \*3 bags

    Drug: Recombinant Human Chymotrypsin(OsrhCT) 4000U

  • Placebo comparator
    Placebo for Recombinant Human Chymotrypsin(OsrhCT)

    Placebo for Recombinant Human Chymotrypsin(OsrhCT) 0U/bag \*3 bags

    Drug: Placebo for Recombinant Human Chymotrypsin(OsrhCT)

Interventions

  • DrugRecombinant Human Chymotrypsin(OsrhCT) 4000U

    Recombinant Human Chymotrypsin (OsrhCT), provided by Wuhan Healthgen Biotechnology Corporation, 4,000U/bag, freeze-dried powder

  • DrugPlacebo for Recombinant Human Chymotrypsin(OsrhCT)

    Recombinant Human Chymotrypsin (OsrhCT), provided by Wuhan Healthgen Biotechnology Corporation, 0 U/bag, freeze-dried powder

06

What researchers measure

Primary outcomes

  1. Total visibility score (TVS) evaluated by blinded endoscopists

    "Total visibility score"counted as the sum of visibility score in lower esophagus, gastric fundus, upper gastric body, lower gastric body and gastric antrum.

    Time frame: Through study completion, up to 2 months

Secondary outcomes

  1. Vsibility scores evaluated by blinded endoscopists for mucosain of 5 various anatomical parts of the stomach

    Vsibility scores for the lower esophagus, antrum, lower gastric body, upper gastric body, and fundus.

    Time frame: Through study completion, up to 2 months

  2. The amount of water flushed for satisfactory observation of the upper gastrointestinal tract

    Amount of water used to allow an suitable visualization of gastric mucosa

    Time frame: During diagnostic upper endoscopy, up to 1 hour

  3. Duration of endoscopy

    Time to complete the upper endoscopy (from the time of oral intubation until complete removal of the endoscope)

    Time frame: During diagnostic upper endoscopy, up to 1 hour

  4. Incidence of adverse events

    Number of gastroscopy procedures with adverse event divided by the number of all gastroscopy procedures. Number of participants with treatment-related adverse events as assessed by CTCAE V6.0.

    Time frame: up to 1 week

07

Study locations

No study locations are listed for this record.

08

References and documents

Individual participant data

Plan to share: No

No publications or documents are linked to this record.

09

Timeline

1 registry update since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reached

Start is estimated for Oct 2026; primary completion for Dec 2026, 1 month later.

How these figures are worked out, and which studies are left out of them.

Registered
Oct 19, 2026
First posted
Oct 26, 2026
StartEst.
Oct 27, 2026
Primary completionEst.
Dec 22, 2026
CompletionEst.
Dec 22, 2026
Last update
Oct 26, 2026
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
Registered
First appeared on the registry. No changes since
Oct 26, 2026
Show all 1 update
  1. Oct 26, 2026
    First appeared on the registry

From the registry record's own update history. This site started tracking changes on Sep 25, 2026; for anything earlier, see the record history on ClinicalTrials.gov ↗

10

Registry details

Key details

Study ID
NCT07893600
Lead sponsor
Healthgen Biotechnology Corp.
Responsible party
Sponsor
First posted
Oct 26, 2026
Start date
Oct 27, 2026 (estimated)
Primary completion
Dec 22, 2026 (estimated)
Completion
Dec 22, 2026 (estimated)
Last update
Oct 26, 2026

Study contacts

Mei Liu, MD
Contact
1744634750@qq.com
+8618627714881
Zhenzhen Zhou, MD
Contact
+8615972196528
Mei Liu, MD
principal investigator · Tongji Hospital

Oversight

Data monitoring committee
No
FDA-regulated drug
No
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is not yet recruiting, as verified in Oct 2026. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Start the discussion